BDNF-inducing peptides
Brain-derived neurotrophic factor sits at the centre of activity-dependent synaptic plasticity. The peptides that induce BDNF in the hippocampus and prefrontal cortex form the most coherent mechanistic family in the cognitive-peptide field. This page collects them, explains what the shared endpoint means, and points to the deeper material on each.
"BDNF peptide" is used loosely for two different things: research peptides that upregulate endogenous BDNF expression (Semax, Selank, Noopept, Cerebrolysin-type preparations, and N-Acetyl analogues), and small peptide mimetics modelled on BDNF's own TrkB-binding loops (loop 2 / loop 4) that act directly at the TrkB receptor rather than raising BDNF levels themselves.
Key facts
Key facts
- Mature BDNF is a 119-amino-acid protein, processed from a ~247-amino-acid pro-form, and signals mainly through the TrkB receptor.
- Mature BDNF also binds the p75NTR receptor.
- BDNF does not cross the blood–brain barrier in meaningful amounts as an intact protein — this delivery limitation is a key reason research has focused on BDNF-inducing peptides and TrkB-binding mimetics rather than on BDNF protein itself.
- Semax has been reported to increase hippocampal BDNF expression in rat studies (Dolotov et al., 2006, Brain Research).
The molecular common ground
What is a BDNF peptide?
BDNF is released by neurons during patterns of activity that drive long-term potentiation — the cellular substrate of memory formation. It binds the TrkB receptor and triggers signalling cascades (PI3K-Akt, MAPK, PLCγ) that stabilise newly active synapses, support neuronal survival under stress, and enable the structural remodelling that turns short-term learning into long-term memory.
Reduced BDNF expression is a consistent feature of depressive states, chronic stress, and age-related cognitive decline. Almost every effective antidepressant treatment — regardless of receptor mechanism — converges on raising BDNF over time. A "BDNF-inducing peptide" is therefore aiming at one of the best-validated cognitive-relevance molecular endpoints currently available.
The peptides catalogued below all show BDNF (and typically NGF) induction in the hippocampus and prefrontal cortex within hours of administration, with persistence for 24+ hours after a single dose and sustained elevation across repeated dosing protocols. The magnitudes vary; the direction is consistent.
The family
Which peptides raise BDNF in research models?
Semax
A synthetic heptapeptide analogue of ACTH(4-10) developed in Russia for cognitive enhancement, neuroprotection, and stroke recovery research.
Selank
A synthetic heptapeptide analogue of tuftsin developed for anxiolytic and immunomodulatory research, with measurable effects on attention and mood.
Cerebrolysin
A complex mixture of low-molecular-weight peptides and free amino acids derived from porcine brain tissue, studied extensively in cognitive decline and post-stroke recovery research.
Noopept (Peptide Note)
A small proline-containing dipeptide derivative — technically a peptidomimetic — developed in Russia as an orally active cognitive enhancer with structural lineage to piracetam.
N-Acetyl Semax Amidate
A chemically protected analogue of Semax with N-terminal acetylation and C-terminal amidation, conferring substantially extended half-life and improved potency in research.
Cortexin
A standardised low-molecular-weight peptide preparation derived from bovine cerebral cortex, used in Russian clinical practice for cognitive impairment, post-stroke recovery, and traumatic brain injury research — the closest single sister to Cerebrolysin.
Cycloprolylglycine
An endogenous cyclic dipeptide that is also the primary active metabolite of Noopept, with intrinsic anxiolytic and cognitive effects independent of its parent compound — a research peptide in its own right.
Org 2766
A classical Dutch/Organon ACTH(4-9) analogue closely related to Semax — the direct pharmacological cousin of the Russian cognitive-peptide programme's flagship compound, with independent memory and neuroprotective research history.
ACTH(4-10)
The parent 4-10 fragment of adrenocorticotropic hormone from which Semax derives — the classical ACTH-fragment cognitive-research peptide with foundational historical significance in the vasopressin/ACTH memory-peptide programme.
Mechanism in detail
How do BDNF-inducing peptides work?
1. Upstream trigger
2. Transcriptional induction
3. TrkB receptor activation
4. Synaptic stabilisation
The translational caveat
What BDNF induction does and doesn't promise
BDNF induction is a molecular endpoint, not a cognitive one. The translation from "we raised BDNF" to "the subject performs better on a learning task" is not automatic. Several variables matter: the magnitude of the induction, the region specificity, the duration of elevation, the baseline state of the system being modulated, and the downstream factors that determine whether elevated BDNF actually produces the expected synaptic and behavioural effects.
The published data show consistent BDNF responses across the family; the cognitive translation is more variable. In healthy young animal models, BDNF induction often fails to produce dramatic cognitive improvements because the baseline is already high. In aged or stressed models — where baseline BDNF is depressed — the effects are more visible. This explains why much of the most striking peptide cognitive-effect data comes from stroke-recovery or aged-rat paradigms rather than from healthy young subjects.
Read the family as "research tools for studying BDNF-mediated cognitive plasticity" rather than as "guaranteed cognitive enhancers". The mechanism is sound; the translation is the open question.
FAQ